Pharmadrug Inc.
Pharmadrug Inc.
PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs. PharmaDrug owns 100% Sairiyo Therapeutics (“Sairiyo”), a biotech company that specializes in researching and reformulating established natural medicines with a goal of bringing them through clinical trials and the associated regulatory approval process in the US and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third party validated potential for the treatment of infectious disease and rare cancers. Sairiyo is also conducting R&D in the psychedelics space for the treatment of non-neuropsychiatric conditions. The Company also owns 100% of Super Smart, a company building a vertically integrated retail business with the goal to elevate the use of functional mushrooms as natural based medicines.
Pharmadrug Inc. (PHRX)
Pharmadrug Inc. (PHRX)
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
*Note: Bid Size and Ask Size fields are displayed as actual quantities
| Bid Broker | Bid Size | Bid Price | Ask Price | Ask Size | Ask Broker |
|---|---|---|---|---|---|
| Desjardins Securities Inc. | 77,000 | 0.01 | 0.015 | 93,000 | iA Private Wealth Inc. |
| Desjardins Securities Inc. | 60,000 | 0.01 | 0.015 | 75,000 | RBC Capital Markets |
| BMO Nesbitt Burns Inc. | 143,000 | 0.01 | 0.015 | 100,000 | Scotia Capital Inc. |
| Questrade Inc. | 30,000 | 0.01 | 0.015 | 50,000 | Anonymous |
| RBC Capital Markets | 52,000 | 0.01 | 0.015 | 1,000 | Desjardins Securities Inc. |
| National Bank Financial Inc. | 59,000 | 0.01 | 0.015 | 9,000 | Raymond James Ltd. |
| Desjardins Securities Inc. | 5,000 | 0.01 | 0.02 | 52,000 | BMO Nesbitt Burns Inc. |
| Desjardins Securities Inc. | 30,000 | 0.01 | 0.02 | 10,000 | CIBC World Markets Inc. |
| RBC Capital Markets | 180,000 | 0.01 | 0.02 | 20,000 | National Bank Financial Inc. |
| Scotia Capital Inc. | 110,000 | 0.01 | 0.02 | 29,000 | National Bank Financial Inc. |
| Bid Broker | Bid Size | Bid Price | Ask Price | Ask Size | Ask Broker |
|---|---|---|---|---|---|
| Anonymous | 200,000 | 0.01 | 0.00 | 0 | |
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 |
| Bid Count | Bid Size | Bid Price | Ask Price | Ask Size | Ask Count |
|---|---|---|---|---|---|
| 28 | 2,039,000 | 0.01 | 0.015 | 328,000 | 6 |
| 13 | 1,309,000 | 0.005 | 0.02 | 785,000 | 18 |
| 0 | 0 | 0.00 | 0.025 | 186,000 | 7 |
| 0 | 0 | 0.00 | 0.03 | 115,000 | 5 |
| 0 | 0 | 0.00 | 0.035 | 533,000 | 7 |
| Bid Count | Bid Size | Bid Price | Ask Price | Ask Size | Ask Count |
|---|---|---|---|---|---|
| 1 | 200,000 | 0.01 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| Date/Time | Price | Change | Volume | Buyer | Seller | Venue |
|---|---|---|---|---|---|---|
| Apr 11, 15:34 | 0.01 | -0.005 | 1,000 | National Bank Financial Inc. | National Bank Financial Inc. | CSE |
| Apr 11, 13:30 | 0.01 | -0.005 | 1,000 | Desjardins Securities Inc. | BMO Nesbitt Burns Inc. | CSE |
| Apr 10, 13:30 | 0.015 | 0.00 | 6,000 | CIBC World Markets Inc. | iA Private Wealth Inc. | CSE |
| Apr 9, 13:30 | 0.015 | 0.00 | 1,000 | National Bank Financial Inc. | iA Private Wealth Inc. | CSE |
| Apr 4, 15:03 | 0.01 | -0.005 | 18,000 | RBC Capital Markets | RBC Capital Markets | CSE |
Company Info
SEDAR Information
Company Info
Capitalization
Company Officers
Bulletins
2023-1038 – Consolidation - Pharmadrug Inc. (PHRX)
le 20 octobre/October 2023
Pharmadrug Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every seven (7) pre-consolidated common shares.
As a result, the outstanding shares of the company will be reduced to approximately 51,518,049 common shares.
The name and symbol will not change.
